The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), a unit of TMC at Kharghar in Navi Mumbai, treated a 17-year-old with a supra-high dose of 131I-mIBG on May 5
Representation pic
A high-dose MIBG (metaiodobenzylguanidine) therapy for treating neuroblastoma, a type of cancer mostly found in children, will be provided at an affordable cost of Rs 7-8 lakh at a research body associated with the Tata Memorial Centre (TMC). The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), a unit of TMC at Kharghar in Navi Mumbai, treated a 17-year-old with a supra-high dose of 131I-mIBG on May 5.
TMC director Dr Sudeep Gupta said the treatment of children with high-risk neuroblastoma, which requires a multi-modality approach including anti-GD2 immunotherapy, costs around Rs 75 lakh and has a long-term cure outcome of 50 per cent.
"The anti-GD2 immunotherapy is exceptionally expensive and inaccessible to many in India. But, the high-dose 131I-mIBG therapy at R7-8 lakh is affordable. With 41 ‘hot beds’ medical isolation ward, the largest in the world, TMC plans to routinely provide this treatment to patients with high-risk neuroblastoma,” he said.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
Subscribe today by clicking the link and stay updated with the latest news!" Click here!
